Endpoint Enabling Study in Cyclin-dependent kinase-like 5 Deficiency Disorder (CDD)
Summary
The study is designed to identify the best outcome measures in assessing their suitability and the adaptability across a variety of countries and languages for future international clinical
trials for patients with CDD.
Eligibility
Eligible gender: Male, Female, Transgender, Other
Inclusion criteria:
Patients ages newborn to 17 years old with documented diagnosis of CDKL5 deficiency
Exclusion criteria:
Any condition that, in the opinion of the investigator, would put the patient at
undue risk or make it unsafe for the patient to participate
Participate
Fill out the following form if you want to participate in this research
Collection of personal information
Your personal information is collected under
the authority of section 33(c) of the Freedom of Information and Protection of Privacy Act. If
you have any questions about the collection or use of this information, please visit our
Access to Information page.
Additional information
Contact information
Dr. Julia Jacobs-LeVan at 4039552480 or Julia.Jacobs-LeVan@albertahealthservices.ca
Principal investigator:
Julia Jacobs-Levan
Clinical trial:
Yes
REB-ID:
REB22-0797